Brozak said the company's growth assumptions are too optimistic, given that government health programs, particularly in debt-laden European countries, are trying to trim their spending."They're talking about a pie ... that's only growing in terms of demand, but who's going to pay for that demand?" he said.
J&J 4Q Profit Jumps On Higher Sales, Lower Charges
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts